X

Drug Profile

Research programme: P2Y receptor agonists - Bar-Ilan University/Innodia

Alternative Names: ID-1738

Latest Information Update: 03 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bar-Ilan University
Class Small molecules
Mechanism of Action Purinoceptor P2U agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Type 2 diabetes mellitus

Most Recent Events

28 Jun 2023 BELLUS Health has been acquired by GSK
17 Jul 2008 Innodia has been acquired by BELLUS Health
30 Mar 2007 Preclinical development is ongoing for ID 1738 in Type-2 diabetes mellitus

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com